End-stage renal disease: endocrine aspects of treatment.
End-stage renal disease (ESRD) is a deadly disease unless supportive treatment is administered in the form of haemodialysis, peritoneal dialysis or kidney transplantation. Although marked improvements have occurred in the efficiency of dialysis and in overall care, patients with ESRD still have poor long-term survival. The outcome is largely dependent on age, nutritional status, efficiency of dialysis and underlying reason for renal failure. As a consequence of renal failure, these patients experience a number of endocrine and metabolic disorders that may affect their well being and overall outcome. Disturbances in the somatotropic axis have been documented at several different levels, including an end-organ resistance to both growth hormone (GH) and insulin-like growth factor-I (IGF-I). A consequence seen in childhood is reduced growth velocity and short final height that may be overcome by long-term GH treatment, and it is possible that metabolism and nutritional status in adults with ESRD may be influenced by these abnormalities. Although a few small trials of GH treatment in adults with ESRD suggest that nutritional status may improve, long-term trials are needed to demonstrate other benefit of such treatment. This review will give a brief description of endocrine problems in adult patients with ESRD with a focus on the somatotropic axis, and it will review the experience reported in published trials of GH treatment in this patient group.
Johannsson
Gudmundur
G
Research Centre for Endocrinology and Metabolism, Sahlgrenska University Hospital, SE-413 45, Gothenburg, Sweden. Gudmundur.Johannson@medic.gu.se
Ahlmén
Jarl
J
D000328:Adult; D012739:Gonadal Steroid Hormones / Q000627:therapeutic use*; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*
D012739:Gonadal Steroid Hormones; D019382:Human Growth Hormone